Browse Technologies
Keyword Search
Antibodies/Protein Therapeutics
Search Results
Displaying: 1 - 10 of 16 Results
Extracellular vesicles for COVID-19 vaccine development
The laboratory of Quan Lu at the Harvard T.H. Chan School of Public Health has developed an innovative vaccine platform that features a novel antigen display technology that has been shown to elicit broadly neutralizing antibody responses from…
DBD
- Grant Zimmermann
Investigators
- Quan Lu
Membrane protein nanoparticles for antigen presentation
Researchers in the lab of Dr. James Chou have engineered a new way to display membrane proteins to enhance vaccine immunogenicity using functionalized nanoparticles. The lab has successfully displayed several viral peptides using this technique and…
DBD
- Grant Zimmermann
Investigators
- James Chou
Printing Microparticles for Drug Delivery
A startup emerging from Jennifer Lewis' lab intends to commercialize a technology platform that can produce microdroplets of highly viscous fluids, with applications in drug formulation and delivery. (Image courtesy of the Lewis Lab.)Droplet-based…
DBD
- Christopher Petty
Investigators
- Jennifer Lewis
Platform for AAV Delivery to Skin
Emerging startup: A platform technology from George Church's lab enables delivery of gene therapy via the skin. (Image credit: Carl Schoellhammer, Denitsa Milanova, Humberto Trevino, Cody Cleveland, Jeff Wyckoff, Anna Mandinova, George Church,…
DBD
- Grant Zimmermann
Investigators
- George Church
Continuous directed evolution of aminoacyl-tRNA synthetases to alter amino acid specificity and enhance activity
DESCRIPTION Functions of various biotherapeutics can often be enhanced by modifying individual amino acid residues. However, the current approaches rely on existing natural amino acid chemistry. Approaches that provide new chemical “handles” will…
DBD
- Irit Ben-Chelouche
Investigators
- David Liu
Novel platform for rapid, immunization-free nanobody discovery
This is a novel platform technology that can be used to expedite the development of nanobodies for therapeutic and diagnostic applications by avoiding the need for animal immunization.Nanobodies are single-domain antibodies derived from camelids…
DBD
- Grant Zimmermann
Investigators
- Andrew Kruse
Anti-cancer Therapeutic Strategy Targeting Ammonium Metabolism
Cancer has long been recognized as a disease of altered cellular metabolism as cancer cells have an abnormally high demand for nutrients to support their growth and proliferation. However, targeting cancer cell metabolism has not been seriously…
DBD
- Irit Ben-Chelouche
Investigators
- Marcia Haigis
- Jessica Spinelli
Intracellular delivery of proteins: Aurin 1.2, an efficient non-endosomal protein delivery platform
To fully realize the therapeutic potential of proteins, exogenous proteins need to access intracellular targets. Since the vast majority of proteins cannot spontaneously cross cell membranes, a range of delivery platforms have been developed. These…
DBD
- Irit Ben-Chelouche
Investigators
- David Liu
Targeting spiral ganglion neurons for treatment of hearing loss
Hearing loss makes interactions with the world challenging for over 30 million people in the United States. While cochlear implants and hearing aid devices can ameliorate hearing loss, they often fail to restore the function of spiral ganglion…
DBD
- Irit Ben-Chelouche
Investigators
- Lisa Goodrich
anti-MARCO monoclonal antibody
The monoclonal antibody recognizes the Macrophage Receptor with Collagenous structure (MARCO). The scavenger receptors (SRs) expressed by macrophages are thought to play an important role in the immune response against bacteria by mediating binding…
DBD
- Grant Zimmermann
Investigators
- Lester Kobzik
- Aiyappa Palecanda